
Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug
Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing inter...





